学习资源
科普文章
克服癌症中CD3+ T细胞重定向相关的挑战(二):TCE与激动剂联用策略[1]
参考文献
1.Singh, A., S. Dees, and I.S. Grewal, Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer, 2021. 124(6): p. 1037-1048.
2.Williams, J.B., et al., The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med, 2017. 214(2): p. 381-400.
3.Weigelin, B., et al., Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A, 2015. 112(24): p. 7551-6.
4.Chiu, D., et al., A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunol Res, 2020. 8(5): p. 596-608.
5.Claus, C., et al., Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine, 2019. 11(496): p. eaav5989.
6.Willems, A., et al., CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother, 2005. 54(11): p. 1059-71.
7.Skokos, D., et al., A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Science Translational Medicine, 2020. 12(525): p. eaaw7888.